Skip to main content
Erschienen in: Investigational New Drugs 3/2014

01.06.2014 | PHASE II STUDIES

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

verfasst von: A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M. G. Daidone, A. M. Gianni, R. Salvioni, F. De Braud

Erschienen in: Investigational New Drugs | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Summary

Despite a compelling preclinical rationale for the use of anti-angiogenic drugs in urothelial cancer (UC), short-living responses have been observed in clinical trials. PF-03446962 is a novel monoclonal antibody against Activin Receptor-Like Kinase-1 (ALK1), a type I subclass of the TGFβ receptor, with dose-dependent anti-angiogenic activity. An open label, single-group, phase 2 trial of PF-03446962 was conducted in salvage setting. Patients failing at least one chemotherapy regimen were eligible. Design provided PF-03446962 10 mg/Kg intravenously fortnightly until disease progression (PD) or unacceptable toxicity. Two-month progression-free survival (PFS) was the primary endpoint. The trial was registered with ClinicalTrials.gov, number NCT01620970. Fourteen patients were enrolled from October 2012 to July 2013. Median age was 64 years (interquartile range [IQR]: 58.2–69.5), 9 patients had a Bellmunt score of 1–2, median number of prior drugs was 3. One stable disease and 13 PD were recorded and the study met the futility stopping rule of interim analysis. Median PFS was 1.8 months (95 %CI, 1.4–2.0). After a median follow up of 7.4 months (IQR 4.5–10.9), 8 patients are alive. Median overall survival (OS) was 8 months (95 %CI, 2.9-not estimable). Most common toxicities were thrombocytopenia (G1-2 in 5 cases, persistent G3 in one, with 3 dose delays and 1 dose interruption), fatigue and abdominal pain (G1-2 in 4 cases each). Impairment of quality of life (ESAS score) was observed as well as an increase from baseline to +2 month median levels of vascular endothelial growth factor (VEGF) and interleukin-8. PF-03446962 had no activity as single drug in refractory UC and we do not recommend further investigation outside of the combination with agents targeting the VEGF receptor axis.
Literatur
1.
Zurück zum Zitat Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861–870CrossRefPubMed Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861–870CrossRefPubMed
2.
Zurück zum Zitat Balar AV, Apolo AB, Ostrovnaya I et al (2013) Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 31:724–730PubMedCentralCrossRefPubMed Balar AV, Apolo AB, Ostrovnaya I et al (2013) Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 31:724–730PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Bellmunt J, González-Larriba JL, Prior C et al (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast-enhancement as potential predictive factors of activity. Ann Oncol 22:2646–2653CrossRefPubMed Bellmunt J, González-Larriba JL, Prior C et al (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast-enhancement as potential predictive factors of activity. Ann Oncol 22:2646–2653CrossRefPubMed
4.
Zurück zum Zitat Dreicer R, Li H, Stein M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the eastern cooperative oncology group. Cancer 115:4090–4095PubMedCentralCrossRefPubMed Dreicer R, Li H, Stein M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the eastern cooperative oncology group. Cancer 115:4090–4095PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Gallagher DJ, Milowsky MI, Gerst SR et al (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28:1373–1379CrossRefPubMed Gallagher DJ, Milowsky MI, Gerst SR et al (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28:1373–1379CrossRefPubMed
6.
Zurück zum Zitat Galsky MD, Hahn NM, Powles T et al (2013) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11:175–181CrossRefPubMed Galsky MD, Hahn NM, Powles T et al (2013) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11:175–181CrossRefPubMed
7.
Zurück zum Zitat Hahn NM, Stadler WM, Zon RT et al (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. J Clin Oncol 29:1525–1530CrossRefPubMed Hahn NM, Stadler WM, Zon RT et al (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. J Clin Oncol 29:1525–1530CrossRefPubMed
9.
Zurück zum Zitat Necchi A, Mariani L, Zaffaroni N et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810–816CrossRefPubMed Necchi A, Mariani L, Zaffaroni N et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810–816CrossRefPubMed
10.
Zurück zum Zitat Pili R, Qin R, Flynn PJ et al (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11:477–483PubMedCentralCrossRefPubMed Pili R, Qin R, Flynn PJ et al (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11:477–483PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Seront E, Rottey S, Sautois B et al (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23:2663–2670CrossRefPubMed Seront E, Rottey S, Sautois B et al (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23:2663–2670CrossRefPubMed
12.
Zurück zum Zitat Grivas PD, Daignault S, Tagawa ST, et al (2013) Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. doi:10.1002/cncr.28477 Grivas PD, Daignault S, Tagawa ST, et al (2013) Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. doi:10.​1002/​cncr.​28477
13.
Zurück zum Zitat Bierie B, Moses HL (2006) TGFβ: the molecular Jeckyll and Hyde of cancer. Nat Rev Cancer 6:506–520CrossRefPubMed Bierie B, Moses HL (2006) TGFβ: the molecular Jeckyll and Hyde of cancer. Nat Rev Cancer 6:506–520CrossRefPubMed
14.
Zurück zum Zitat Champelovier P, El Atifi M, Mantel F et al (2005) In vitro tumoral progression of human bladder carcinoma: role for TGFbeta. Eur Urol 48:846–851CrossRefPubMed Champelovier P, El Atifi M, Mantel F et al (2005) In vitro tumoral progression of human bladder carcinoma: role for TGFbeta. Eur Urol 48:846–851CrossRefPubMed
15.
Zurück zum Zitat Lamouille S, Mallet C, Feie JJ et al (2002) Activin receptor like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100:4495–4501CrossRefPubMed Lamouille S, Mallet C, Feie JJ et al (2002) Activin receptor like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100:4495–4501CrossRefPubMed
16.
Zurück zum Zitat Oh SP, Seki T, Goss KA et al (2000) Activin receptor like-kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. PNAS 97:2626–2631PubMedCentralCrossRefPubMed Oh SP, Seki T, Goss KA et al (2000) Activin receptor like-kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. PNAS 97:2626–2631PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Scharpfenecker M, van Dinther M, Liu Z et al (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964–972CrossRefPubMed Scharpfenecker M, van Dinther M, Liu Z et al (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964–972CrossRefPubMed
18.
Zurück zum Zitat Hu-Lowe DD, Chen E, Zhang L et al (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71:1362–1373PubMedCentralCrossRefPubMed Hu-Lowe DD, Chen E, Zhang L et al (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71:1362–1373PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Goff L, Cohen RB, Berlin J, et al (2011) Phase I study of PF-03446962, a fully human mAb against ALK1, a TGFβ receptor involved in tumor angiogenesis. J Clin Oncol 29(suppl; abstr 3009) Goff L, Cohen RB, Berlin J, et al (2011) Phase I study of PF-03446962, a fully human mAb against ALK1, a TGFβ receptor involved in tumor angiogenesis. J Clin Oncol 29(suppl; abstr 3009)
20.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
21.
Zurück zum Zitat Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using (18 F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for the Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35:1773–1782CrossRefPubMed Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using (18 F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for the Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35:1773–1782CrossRefPubMed
22.
Zurück zum Zitat Moro C, Brunelli C, Miccinesi G et al (2006) Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14:30–37CrossRefPubMed Moro C, Brunelli C, Miccinesi G et al (2006) Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14:30–37CrossRefPubMed
23.
Zurück zum Zitat Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850–1855CrossRefPubMed Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850–1855CrossRefPubMed
24.
Zurück zum Zitat Necchi A, Mariani L, Giannatempo P, et al (2013) Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2013.11.022 Necchi A, Mariani L, Giannatempo P, et al (2013) Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Clin Genitourin Cancer. doi:10.​1016/​j.​clgc.​2013.​11.​022
25.
Zurück zum Zitat Bendell JC, Gordon MS, Hurwits HI et al (2013) Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res 20:1–10 Bendell JC, Gordon MS, Hurwits HI et al (2013) Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res 20:1–10
26.
Zurück zum Zitat Bhatt RS, Wang X, Solban N, et al (2013) Inibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol 31(suppl 6; abstr 370) Bhatt RS, Wang X, Solban N, et al (2013) Inibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol 31(suppl 6; abstr 370)
27.
Zurück zum Zitat Atkins MB, Bhatt RS, Voss MH, et al (2013) Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. J Clin Oncol 31(suppl; abstr TPS4595) Atkins MB, Bhatt RS, Voss MH, et al (2013) Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. J Clin Oncol 31(suppl; abstr TPS4595)
28.
Zurück zum Zitat Jimeno A, Wirth LJ, Posner MR, et al (2013) Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 31(suppl; abstr TPS6098) Jimeno A, Wirth LJ, Posner MR, et al (2013) Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 31(suppl; abstr TPS6098)
29.
Zurück zum Zitat Sonpavde G, Bellmunt J, Rosenberg JE, et al (2014) Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 353) Sonpavde G, Bellmunt J, Rosenberg JE, et al (2014) Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 353)
30.
Zurück zum Zitat Sonpavde G, Bellmunt J, Rosenberg JE et al (2014) Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 336) Sonpavde G, Bellmunt J, Rosenberg JE et al (2014) Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 336)
Metadaten
Titel
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
verfasst von
A. Necchi
P. Giannatempo
L. Mariani
E. Farè
D. Raggi
M. Pennati
N. Zaffaroni
F. Crippa
A. Marchianò
N. Nicolai
M. Maffezzini
E. Togliardi
M. G. Daidone
A. M. Gianni
R. Salvioni
F. De Braud
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 3/2014
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-014-0074-9

Weitere Artikel der Ausgabe 3/2014

Investigational New Drugs 3/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.